Resapp Health : to Exhibit at the McKinsey Future of Digital Healthcare Conference in Dubai

View printer-friendly version

ResApp Health Limited (ASX: RAP), the developer of smartphone medical applications for the diagnosis and management of respiratory disease, is pleased to announce that the company has accepted an invitation to exhibit at McKinsey & Company's The Future of Digital Healthcare Conference to be held on the 27th and 28th of January 2016 at The One and Only Royal Mirage Hotel in Dubai. The conference will focus on how digital and analytics are transforming healthcare. Attendees will include CEOs, board members and senior executives of major hospitals, government officials and health insurance company representatives from the Middle East.

'This conference represents an exciting opportunity to demonstrate ResApp's diagnostic technology in the Middle East where governments have clearly identified telehealth and digital health as essential tools for reducing the growing strain on healthcare resources,' said Dr Tony Keating, CEO and Managing Director of ResApp. 'There are also opportunities for ResApp to help deliver quality healthcare to people living in resource-limited and turbulent zones across the region.'

ResApp filed a Pre-Submission package with the US FDA at the end of last calendar year, marking a major step towards FDA approval. The FDA has completed their administrative review of the submission and a meeting is scheduled to take place this quarter.

- ENDS -

About ResApp Health Limited
ResApp Health Limited, founded in 2014, is developing smartphone medical applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use sound alone to diagnose and measure the severity of respiratory conditions without the need for additional hardware. The algorithms were initially developed by The University of Queensland with funding from the Bill and Melinda Gates Foundation. ResApp has a multi-site clinical study underway and preliminary results demonstrated accurate diagnosis of pneumonia, asthma/viral wheeze, bronchiolitis, croup and upper respiratory tract infections in children. Approval has been recently received to extend the study to adults. Markets for ResApp's technology include telehealth use through partnerships with telehealth service providers, emergency department and regular clinic use by healthcare providers, at-home use by consumers and working with global aid and humanitarian organisations to deliver tools for the developing world.

For more information on ResApp, visit www.resapphealth.com.au